Hygroton (Chlortalidone)

Chlortalidone works by blocking the Na+/Cl- symporter in the distal convoluted tubule of the kidney. This inhibition reduces sodium and chloride reabsorption, leading to increased urinary loss of these electrolytes along with water, which lowers plasma volume and blood pressure.

The appropriate dose of chlortalidone is individualized by the prescribing clinician based on the patient’s condition, response, and renal function. Dosage may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional.

Chlortalidone is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so caution is advised.

To order Hygroton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hygroton (chlortalidone) is a thiazide‑like diuretic, generally considered more potent and longer‑acting than traditional thiazides such as hydrochlorothiazide. It often achieves greater blood‑pressure reduction at lower doses, but the choice of agent depends on individual patient factors and tolerability.

Store Hygroton tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or other humid environments.

Hygroton is taken orally, usually with a full glass of water. It can be taken with or without food, but consistency with meals may help reduce stomach irritation. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

Serious risks include severe electrolyte disturbances such as hypokalemia or hyponatremia, marked dehydration, gout attacks, acute pancreatitis, and rare blood disorders like agranulocytosis. Patients should report symptoms like muscle weakness, irregular heartbeat, severe abdominal pain, or unexplained fever promptly.

Hygroton should be avoided in patients with anuria, severe renal impairment, known hypersensitivity to chlortalidone or other sulfonamide drugs, and in those with severe hepatic disease. Caution is also advised for individuals with gout, diabetes, or a history of electrolyte abnormalities.